Illinois Department of Public Health
Pauses Use of Johnson & Johnson COVID-19 Vaccine
Illinois Follows CDC and FDA Guidance,
Advises Providers to Use Moderna and Pfizer Doses for Existing
Appointments
Send a link to a friend
[April 29, 2021]
In accordance with recommendations from the
U.S. Centers for Disease Control and Prevention (CDC) and the U.S.
Food and Drug Administration (FDA), the Illinois Department of
Public Health (IDPH) will pause the use of the Johnson & Johnson
(J&J) COVID-19 vaccine out of an abundance of caution. The CDC and
FDA are reviewing data involving six reported U.S. cases of a rare
and severe type blood clot in individuals after receiving the J&J
vaccine.
|
IDPH has notified all Illinois COVID-19 providers
throughout the state to discontinue use of the J&J vaccine at this
time. In order to keep appointments, IDPH is strongly advising
providers to use Pfizer-BioNTech and Moderna vaccines.
Moderna and Pfizer make up the vast majority of doses on hand in the
State of Illinois. This week, the state’s allocation of J&J was
17,000 doses. For the week of April 18, 2021, the expected
allocation for the State is 483,720 total doses. Of that total
allocation, 5,800 doses were expected to be J&J.
[to top of second column] |
Per the federal health authorities, people who have
received the J&J vaccine who develop severe headache, abdominal
pain, leg pain, or shortness of breath within three weeks after
vaccination should contact their health care provider. Patients with
other clinical questions should contact their health care provider.
IDPH will continue to update the public as additional information
becomes available.
[TIllinois Office of Communication
and Information] |